ClinicalTrials.gg

Program

turigrobart

Its studies are mostly in Neuralgia, led by Eli Lilly.

Furthest: phase 2, since Aug 21, 20242 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly20 open or runningphase 2since Aug 21, 2024Feb 5, 2023none ahead
  • Named in Eli Lilly’s own pipeline as Turigrobart, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 5, 2023First study: phase 1 study in HealthyFirst studyNCT05727072 · 64 enrolled · United States
  2. Aug 21, 2024Phase 2 study in NeuralgiaNCT06568042 · 558 enrolled · United States, Canada, Germany and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06568042Neuralgia · United States, Canada, Germany and more2CompletedJan 12, 2026558
NCT05727072Healthy · United States1CompletedFeb 19, 202464

How it is read

Names in the registry

  • “LY3848575”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.